Gapping up
In reaction to strong earnings/guidance:
- EHTH +13.4%, MAT +10.8%, KNL +9.6%, PRO +8.2%, SFLY +7.9%, F +7.4%, GRUB +5.9%, AON +5%, BLMN +4.4%, CVA +4.3%, TREE +4.2%, POR +3.9%, WPP +3.6%, COLM +3.4%, LOGM +3.2%, BJRI +2.8%, BOOM +2.5%, SNY +2.5%, GVA +2.5%, COF +2.2%, IMAX +2.2%, CY +2%, SWN +2%, RSG +1.9%, SNE +1.4%, AN +1.3%, BABY +1.2%, CL +1.1%, FET +1%, AMZN +0.9%, PFG +0.9%, HRC +0.9%, DRQ +0.8%, OMCL +0.7%, TMUS +0.7%, .
M&A news:
- PETX +37% (to be acquired by Elanco Animal Health (ELAN) for an implied value of $4.75/share in stock + a CVR)
Other news:
- RBBN +4% (discloses binding mediator's proposal that resolves the six previously disclosed lawsuits between the Company and Metaswitch )
- ZAYO +2.9% (drifting higher in extended trading on light volume amid renewed M&A chatter), GM +2.5% (following F earnings/guidance)
- MMYT +1.8% (announces change in shareholding as a result of share exchange transaction agreement between Naspers (NPSNY) and Ctrip.com (CTRP))
- SBBP +1.3% (light volume; presents new secondary endpoint results from the Phase 3 SONICS study of RECORLEV for the potential treatment of endogenous Cushing's syndrome)
- CNC +1.1% (following CEO appearance on MadMoney)
Analyst comments:
- MDCO +8.5% (upgraded to Buy from Neutral at Goldman)
- TEUM +6.4% (initiated with Outperform rating and $7 tgt at Oppenheimer)
- TOCA +4.3% (initiated with a Overweight at Cantor Fitzgerald; tgt $28 - sees high likelihood of Phase 3 Glioma success in 2019)
- CLF +2.5% (upgraded to Outperform from Neutral at Credit Suisse)
- ESPR +1.6% (upgraded to Neutral from Sell at Goldman)
- MAS +1.3% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- DRI +1% (initiated with a Buy at UBS)
- HEXO +0.8% (initiated with Buy at Desjardins)
- CNSL +0.5% (upgraded to Outperform from Market Perform at Wells Fargo)